PTCT vs BLTE
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
PTCT · PTC Therapeutics$56.42 ▼ 3.27%
BLTE · Belite Bio$127.38 ▼ 15.65%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- PTCT -29.3%
- BLTE -6.3%
Head to head
| Metric | PTCT | BLTE |
|---|---|---|
| Price | $56.42 | $127.38 |
| Change today | ▼ 3.27% | ▼ 15.65% |
| Market cap | $4.71B | $5.17B |
| Return, 3 months | -20.6% | -19.8% |
| Return, year to date | -25.7% | -20.4% |
| Return, 1 year | -28.1% | +5.7% |
| P/E (TTM) | – | – |
| P/B | -24.6 | 6.7 |
| P/E percentile vs own 5y | 6th | 40th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +69.6% | – |
| Net profit growth (YoY) | -425.2% | -39.6% |
| Gross margin | 93.2% | – |
| Operating margin | 12.0% | – |
| Net margin | -9.2% | – |
| Return on equity | – | -21.2% |
| Analyst target vs. price | +77.2% | +81.9% |
| Analyst buy share | 83% | 100% |
| RSI (14) | 34 | 32 |
| 30-day volatility | 54.4% | 74.4% |
| Max drawdown, 1 year | -37.0% | -34.2% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- BLTE is the largest of the group by market value.
- BLTE has returned the most over the past year.
- PTCT has been the calmest stock over the last 30 days.